Render Target: STATIC
Render Timestamp: 2024-12-03T10:50:38.684Z
Commit: cd2fae6ca3f811b1ddb1df24ac291ed56d5d501b
XML generation date: 2024-11-26 23:01:10.376
Product last modified at: 2024-12-02T09:00:11.276Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

TCEB2/Elongin B (F1K9D) Rabbit mAb #82297

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R Mk
    SENSITIVITY Endogenous
    MW (kDa) 18
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 
    • Mk-Monkey 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    TCEB2/Elongin B (F1K9D) Rabbit mAb recognizes endogenous levels of total TCEB2/Elongin B protein. Based on sequence homology, this antibody is not predicted to cross-react with TCEB1/Elongin C protein.

    Species Reactivity:

    Human, Mouse, Rat, Monkey

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human TCEB2/Elongin B protein.

    Background

    Transcription elongation factor B polypeptide 2 (TCEB2), also known as Elongin B, is a regulatory component of the SIII/Elongin elongation complex, which regulates elongation by RNA polymerase II by suppressing pausing of the polymerase during gene transcription. The SIII/Elongin complex is also composed of TCEB3/Elongin A, the catalytic subunit, and TCEB1/Elongin C, another regulatory subunit (1). TCEB2/Elongin B is part of the ubiquitin-proteasome pathway as a critical component of multiple E3 ligase complexes. It directly interacts with TCEB1/Elongin C as part of the VHL complex, which targets HIF-1α, a transcription factor that plays a critical role in the cellular response to hypoxia, for degradation (2,3). Dysregulation of HIF-α activity is associated with poor prognosis in multiple human cancers (4). TCEB2/Elongin B promotes therapy resistance in ovarian cancer (5,6), promotes breast cancer progression (7), and reduces radiosensitivity in triple-negative breast cancer (TNBC) (8). During HIV-1 infection, TCEB2/Elongin B is part of an E3 ligase complex that targets the anti-viral proteins APOBEC3F and APOBEC3G for degradation (9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.